Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Ping Lu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0377-9481; OpenAlex author ID A5100610321. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
37
Papers, trials and grants by year

2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 9

  1. Targeting pancreatic cancer glutamine dependency confers vulnerability to GPX4-dependent ferroptosis. Co-author DOI 10.1016/j.xcrm.2025.101928↗
  2. Tumor cell-intrinsic epigenetic dysregulation shapes cancer-associated fibroblasts heterogeneity to metabolically support pancreatic cancer. Co-author DOI 10.1016/j.ccell.2024.03.005↗
  3. Glycolysis addiction compensating for a defective pentose phosphate pathway confers gemcitabine sensitivity in SETD2-deficient pancreatic cancer. Co-author DOI 10.1016/j.bbrc.2022.05.047↗
  4. SULF2 enhances GDF15-SMAD axis to facilitate the initiation and progression of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.215693↗
  5. CD74 promotes perineural invasion of cancer cells and mediates neuroplasticity via the AKT/EGR-1/GDNF axis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2021.03.016↗
  6. Perineural Invasion Reprograms the Immune Microenvironment through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-19-2689↗
  7. CD90 highly expressed population harbors a stemness signature and creates an immunosuppressive niche in pancreatic cancer. First author DOI 10.1016/j.canlet.2019.03.051↗
  8. THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer. Co-author DOI 10.1038/s41388-019-0701-1↗
  9. IL22RA1/STAT3 Signaling Promotes Stemness and Tumorigenicity in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-17-3131↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jing Xue · 8 shared papers, 2018–2025 · strength 0.99
  2. Ningning Niu · 7 shared papers, 2019–2025 · strength 0.92
  3. Yongwei Sun · 8 shared papers, 2018–2024 · strength 0.88
  4. Xuqing Shen · 4 shared papers, 2022–2025 · strength 0.66
  5. Minwei Yang · 6 shared papers, 2018–2024 · strength 0.66
  6. Yingying Tang · 2 shared papers, 2024–2025 · strength 0.39
  7. Yan‐Miao Huo · 4 shared papers, 2018–2022 · strength 0.39
  8. Liwei Wang · 3 shared papers, 2019–2025 · strength 0.39
  9. Jian‐Yu Yang · 3 shared papers, 2020–2022 · strength 0.32
  10. Xueliang Fu · 3 shared papers, 2020–2022 · strength 0.32
  11. Dejun Liu · 3 shared papers, 2020–2022 · strength 0.32
  12. Juanjuan Shi · 3 shared papers, 2019–2022 · strength 0.32
  13. Ruizhe He · 3 shared papers, 2019–2022 · strength 0.30
  14. Juanjuan Shi · 3 shared papers, 2018–2022 · strength 0.28
  15. Yuan Fang · 3 shared papers, 2018–2019 · strength 0.25
  16. Zhigang Zhang · 3 shared papers, 2018–2020 · strength 0.23
  17. Tiebo Mao · 1 shared paper, 2025 · strength 0.22
  18. Yongsheng Jiang · 2 shared papers, 2020–2022 · strength 0.20
  19. Rong Hua · 2 shared papers, 2020–2021 · strength 0.20
  20. Shu‐Heng Jiang · 2 shared papers, 2020–2021 · strength 0.20
  21. Zipeng Lu · 1 shared paper, 2024 · strength 0.17
  22. Liwei Wang · 1 shared paper, 2024 · strength 0.17
  23. Jiabin Jin · 1 shared paper, 2024 · strength 0.17
  24. Kuirong Jiang · 1 shared paper, 2024 · strength 0.17
  25. Baiyong Shen · 1 shared paper, 2024 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.